DRG Market Assessment 보고서

Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma and are a common indication for liver transplantation. The late 2013 FDA…

LaunchTrends: Cosentyx (US) is a three-wave syndicated report series that specifically tracks the introduction of Novartis’s Cosentyx (secukinumab), a potent, subcutaneous IL-17 inhibitor…

Amid Significant Unmet Need, What Magnitude of Efficacy and Safety Do Endocrinologists and Payers Expect of New and Emerging Therapies? The evidence demonstrating the serious physical, economic…

In This Underserved Arena, What Clinical Attributes Will Be Most Persuasive for Neurologists and Payers Regarding Novel Outpatient Rescue Therapies? Acute repetitive seizures (ARS)—also known…

What Attributes of Emerging Therapies Will Most Influence Both Physicians’ and Payers’ Decisions to Effectively Position These Biologics Against IV Belimumab? Systemic lupus erythematosus (…

TreatmentTrends®: Malignant Melanoma Q2 2015 (US) is the first in a series of reports that examines current trends in the management of unresectable or metastatic malignant melanoma from the…

With the Entry of New Oral and Biological Agents, Where Are the Remaining Areas of Opportunity in an Increasingly Crowded Market? Affecting more than three million people in the major…

How Will the Rise in Antibiotic Resistance Shape the U.S. Prescribing and Reimbursement Environment for Novel Antibiotics? Although antibiotics from several drug classes are available to treat…

A Survey of Nephrologists and Interviews with Payers in the EU5 Renal anemia and hyperphosphatemia, or elevated serum phosphorous, are two primary complications of chronic kidney disease (CKD)…

How Does Cost Versus Dosing Impact Prescriber Preferences and Payer Policy? Agents that target vascular endothelial growth factor (VEGF) have expanded the treatment armamentarium in Brazil and…

Payer and Physician Receptivity to Oral HIF-PH Inhibitors and Other Novel Treatments: Which Emerging Drugs Excite Them? Renal anemia is one of the primary complications of chronic kidney disease (…

Cancer immunotherapy is one of the most exciting fields of research in oncology. Successful drug development in this space offers a highly lucrative opportunity for drug developers. Most excitement…